Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OncoMed Pharmaceuticals, Inc.

http://www.oncomed.com

Latest From OncoMed Pharmaceuticals, Inc.

Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T

The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.

Companies Strategy

Surrozen Inks First Partnership With BI For Wnt-Targeted Retinopathy Candidate

German pharma takes global rights to preclinical bispecific antibody, while Surrozen will focus on Phase I candidates for inflammatory bowel disease and alcoholic hepatitis.

Deals Business Strategies

Galapagos Keeps Analysts Guessing About Future Plans

Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.

Sales & Earnings Clinical Trials

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals
See All

Company Information

UsernamePublicRestriction

Register